Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
FRA:818'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.34 Med: -0.16 Max: 0.65
Current: 0.27
During the past 7 years, the highest Debt-to-EBITDA Ratio of Zylox-Tonbridge Medical Technology Co was 0.65. The lowest was -1.34. And the median was -0.16.
FRA:818's Debt-to-EBITDA is ranked better than 80.34% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs FRA:818: 0.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Related Terms
Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Chart
FRA:818 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Zylox-Tonbridge Medical Technology Co (FRA:818) has a Debt-to-EBITDA of 0.28 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zylox-Tonbridge Medical Technology Co. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #93 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 19.7%.
Is Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA too high?
Zylox-Tonbridge Medical Technology Co's current Debt-to-EBITDA is 0.28. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Zylox-Tonbridge Medical Technology Co's value of 0.28 is 82.7% below this industry median. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #93 out of 473 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #93 out of 473 companies for Debt-to-EBITDA. This places Zylox-Tonbridge Medical Technology Co in the top 20% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Zylox-Tonbridge Medical Technology Co's value of 0.28 is 82.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current Debt-to-EBITDA of 0.28 is 82.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zylox-Tonbridge Medical Technology Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current Debt-to-EBITDA is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current Debt-to-EBITDA is 0.28 and 82.7% below the Medical Devices & Instruments industry median of 1.62. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current Debt-to-EBITDA is 0.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:818:
Debt-to-EBITDA: 0.28
GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
Industry Position: 82.7% below the Medical Devices & Instruments median (#93 of 473)
No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score
Get the complete analysis for FRA:818
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:818 has been successfully added to your 
